News Outlets Discuss Various Aspects Of COVID-19 Vaccine R&D, Availability, Licensing; Antibody Drug Access; Operation Warp Speed Leadership; Drug Shortages

CNBC: ‘Learn to live with the pandemic’: Physicians warn that a vaccine may not prevent Covid from becoming endemic (Meredith, 10/22).

The Hill: Azar says COVID-19 vaccine could be delivered to vulnerable people by January (Axelrod, 10/22).

NPR: How Will The Limited Supply Of Antibody Drugs For COVID-19 Be Allocated? (Harris, 10/21).

STAT: Blood plasma showed no benefit in Covid-19 patients in trial — a finding that could re-energize debate (Garde/Herper, 10/22).

STAT: ‘A matter of life and death’: Why a Brazilian lawmaker wants compulsory licensing for Covid-19 products (Silverman, 10/22).

STAT: Democrats want to fire Warp Speed’s Moncef Slaoui and overhaul the program. But if Biden wins, should he? (Florko, 10/22).

STAT: As Covid-19 intensifies, shortages of staple drugs may grow worse (Silverman, 10/21).

Washington Post: Moderna’s coronavirus vaccine trial is fully enrolled, 37 percent of participants are minorities (Johnson, 10/22).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.